Dynamic Contrast-enhanced Magnetic Resonance Imaging for Patients with Breast Cancer Receiving First-line Bevacizumab and Paclitaxel. [electronic resource]
Producer: 20180917Description: 5459-5463 p. digitalISSN:- 1791-7530
- Adult
- Aged
- Angiogenesis Inhibitors -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Bevacizumab -- administration & dosage
- Breast Neoplasms -- diagnostic imaging
- Contrast Media -- administration & dosage
- Disease Progression
- Female
- Humans
- Japan
- Magnetic Resonance Imaging
- Meglumine -- administration & dosage
- Middle Aged
- Organometallic Compounds -- administration & dosage
- Paclitaxel -- administration & dosage
- Predictive Value of Tests
- Prospective Studies
- Remission Induction
- Time Factors
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial; Journal Article
There are no comments on this title.
Log in to your account to post a comment.